Moreover, BRAF mutations are associated with adverse clinical outcomes in patients with CRC, with a 70% increase in mortality in patients with metastatic CRC harboring BRAFV600E mutations compared with those carrying wild-type BRAF3, 4. This evidence concerns the gene BRAF and colorectal carcinoma.